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Abstract
GPR37 is an orphan G protein- coupled receptor (GPCR) implicated in several neu-
rological diseases and important physiological pathways in the brain. We previously 
reported that its long N- terminal ectodomain undergoes constitutive metalloprotease- 
mediated cleavage and shedding, which have been rarely described for class A GPCRs. 
Here, we demonstrate that the protease that cleaves GPR37 at Glu167↓Gln168 is 
a disintegrin and metalloprotease 10 (ADAM10). This was achieved by employ-
ing selective inhibition, RNAi- mediated downregulation, and genetic depletion of 
ADAM10 in cultured cells as well as in vitro cleavage of the purified receptor with 
recombinant ADAM10. In addition, the cleavage was restored in ADAM10 knock-
out cells by overexpression of the wild type but not the inactive mutant ADAM10. 
Finally, postnatal conditional depletion of ADAM10 in mouse neuronal cells was 
found to reduce cleavage of the endogenous receptor in the brain cortex and hip-
pocampus, confirming the physiological relevance of ADAM10 as a GPR37 shed-
dase. Additionally, we discovered that the receptor is subject to another cleavage step 
in cultured cells. Using site- directed mutagenesis, the site (Arg54↓Asp55) was local-
ized to a highly conserved region at the distal end of the ectodomain that contains a 
recognition site for the proprotein convertase furin. The cleavage by furin was con-
firmed by using furin- deficient human colon carcinoma LoVo cells and proprotein 
convertase inhibitors. GPR37 is thus the first multispanning membrane protein that 
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1 |  INTRODUCTION
The G protein- coupled receptor 37 (GPR37) is a class A 
(rhodopsin- type) G protein- coupled receptor (GPCR) that is 
highly expressed in several brain regions.1 It is involved in 
dopaminergic and adenosinergic signaling pathways,2- 6 and 
consequently has been implicated in the pathophysiology 
of Parkinson's disease7,8 along with certain other brain pa-
thologies.9,10 The receptor is also found in astrocytes,11 and 
especially in oligodendrocytes,12,13 with a demonstrated role 
in their differentiation and myelination.13 Thus, GPR37 is a 
promising target for the treatment of neurological diseases. 
However, attempts to identify the activating ligand for GPR37 
have resulted in controversial results [reviewed14,15], and the 
receptor is still considered an orphan GPCR. Moreover, the 
mechanisms, by which GPR37 is activated and regulated in 
cells, are poorly understood.
We have previously demonstrated that the long extra-
cellular N- terminus of human GPR37 (238 amino acids) is 
subject to constitutive proteolytic cleavage between Glu167 
and Gln168 in cultured cells and that the cleaved ecto-
domain is shed to the culture medium.16 In line with this 
finding, the cerebrospinal fluid has been shown to contain 
GPR37 N- terminal peptides,17,18 suggesting that the proteo-
lytic processing of the receptor occurs in native brain tissue. 
Indeed, we reported recently that these peptides are elevated 
in Parkinson's disease patients.18 While ectodomain cleavage 
and shedding are common mechanisms regulating single- 
pass membrane proteins, these mechanisms have quite rarely 
been described for multi- spanning membrane proteins, such 
as GPCRs. Important exceptions include adhesion family 
receptors and protease- activated receptors (PARs) that dis-
play a unique activation mechanism involving N- terminal 
proteolytic processing.19,20 Whereas the former receptors are 
characteristically cleaved in the endoplasmic reticulum in an 
autoproteolytic manner, PARs are cleaved by extracellular 
proteases at the cell surface. For both GPCR subgroups, the 
limited proteolysis reveals a new N- terminus that acts as a 
tethered peptide agonist and activates the receptor. Examples 
of other GPCRs that are cleaved at their N- terminal ecto-
domain have remained scarce and in most cases, the cleav-
age mechanism and its functional consequences are poorly 
known. Intriguingly, among these few GPCRs are two recep-
tors closely related to GPR37, the endothelin B receptor, and 
GPR37L1.21,22 Whereas GPR37L1, an orphan receptor- like 
GPR37, is cleaved constitutively, cleavage of the endothelin 
B receptor occurs in an agonist- dependent manner and has 
been found to alter receptor function in vascular smooth mus-
cle cells.23
Proteolytic processing of membrane proteins involves sev-
eral proteases, many of which belong to proprotein convertase 
(PC) and metalloprotease families. PCs comprise a family of 
nine secretory serine proteases that activate, or in some cases 
inactivate, secreted or membrane- bound proteins by cleav-
ing them at specific sites.24 Their substrates range from hor-
mones and cytokines to growth factors, receptors, and other 
proteases [reviewed24], highlighting the role of PCs in many 
vital biological processes. MMPs (matrix metalloproteases) 
and ADAMs (a disintegrin and metalloproteases) constitute 
the main metalloprotease families involved in limited pro-
teolysis and shedding,25,26 Among these, ADAM10, along 
with ADAM17, is the most extensively characterized proteo-
lytically active ADAM family member.26,27 ADAM10 is in-
volved in the cleavage and shedding of several type I and II or 
glycosylphosphatidylinositol- anchored membrane proteins, 
including Notch, amyloid precursor protein, N- cadherin, 
ephrins 2 and 5, and cellular prion protein [reviewed26,27]. 
In comparison, the possible role of ADAM10 in the cleavage 
of multi- spanning membrane proteins has remained elusive, 
although a few ADAM10 candidate substrates have emerged 
in proteomic studies.28
In our previous study, we showed that metalloproteases 
are involved in GPR37 processing as the cleavage is sig-
nificantly reduced with broad- spectrum metalloprotease in-
hibitors at the Glu167↓Gln168 site.16 However, the actual 
enzymes involved in GPR37 processing and their mecha-
nisms of action have remained unknown. As GPR37 is found 
at the plasma membrane predominantly in its N- terminally 
truncated form,16 a better understanding of receptor cleavage 
mechanisms and identification of the proteases involved will 
benefit studies aiming to assess GPR37 activation and sig-
naling mechanisms. In the present study, we set out to iden-
tify the specific enzymes involved in GPR37 processing. We 
demonstrate that ADAM10 cleaves human and mouse GPR37 
(hGPR37 and mGPR37, respectively) in cultured cells, and 
furthermore participates in receptor processing in the mouse 
brain. In addition, GPR37 is processed by the PC furin at 
a highly conserved site in the distal end of the N- terminal 
has been validated as an ADAM10 substrate and the first GPCR that is processed by 
both furin and ADAM10. The unconventional N- terminal processing may represent 
an important regulatory element for GPR37.
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domain (Arg54↓Asp55of hGPR37). Thus, this study provides 
evidence for diverse multistep proteolytic processing of a 
class A orphan GPCR involving proteases belonging to two 
distinct families, PCs and ADAMs.
2 |  MATERIALS AND METHODS
2.1 | Chemicals and antibodies
Protease inhibitors were obtained from Tocris Bioscience 
[decanoyl- RVKR- chloromethylketone (decCMK), 
GI254023X, marimastat; Abingdon, UK], Enzo Life Sciences 
(aprotinin, GM6001, leupeptin; Farmingdale, NY, USA), 
Calbiochem (hexa- D- arginine; San Diego, CA, USA), Merck 
Millipore (inactive GM6001, TAPI- 1; Burlington, MA, USA) 
or Sigma- Aldrich (E- 64d, pepstatin A, phosphoramidon; St. 
Louis, MO, USA). The recombinant (r) human ADAM10 
was obtained from R&D Systems (936- AD; Abingdon, UK). 
The following commercially available primary polyclonal and 
monoclonal antibodies (pAb and mAb, respectively) were 
used for Western blotting: cMyc [rabbit pAb A14, sc- 789, 
1:1000; SantaCruz Biotechnology (Dallas, Tx, USA) and 
mouse mAb 9E10, 626802, 1:1000; BioLegend (San Diego, 
CA, USA)], FLAG [HRP- conjugated mouse mAb M2, A8592, 
1:50  000, Sigma- Aldrich], translocon- associated protein α- 
subunit (TRAPα, rabbit pAb 10583- 1- AP, 1:2000; Proteintech, 
Manchester, UK), ADAM10 [rabbit pAb ab1997, 1:1000, 
Figure  3 and rabbit mAb (EPR5622) ab124695, 1:2000, 
Figure 9; Abcam, Cambridge, UK], ADAM17 (rabbit pAb ADI- 
905- 249, 1:2000; Enzo Life Sciences) and α- actinin (mouse 
mAb B- 12, sc- 166524, 1:1000; Santa- Cruz Biotechnology). 
The rabbit pAbs directed against hGPR37 and mGPR37 N- 
terminal domain and GPR37 C- terminal domain (all used at 
0.5- 2 µg/mL) have been described previously.2,5,29 Mouse and 
rabbit HRP- conjugated secondary antibodies were obtained 
from Sigma- Aldrich or Thermo Fisher Scientific (GENA9310 
and GENA9340, 1:40  000; 31460 and 31430, 1:10  000, re-
spectively). The antibodies for confocal microscopy were: 
cMyc (rabbit pAb C3956, 2 µg/mL; Sigma- Aldrich), α- 1 Na+/
K+ ATPase [mouse mAb (464.6) ab7671, 2 µg/mL; Abcam] 
and Alexa Fluor 488 and 568 goat anti- rabbit IgG (A11008 
and A11004, respectively, 8 µg/mL; Invitrogen, Carlsbad, CA, 
USA). All other reagents were purchased from Sigma- Aldrich 
or Thermo Fisher Scientific unless indicated otherwise.
2.2 | Animals
Eight- week- old C57BL/6J wild type (WT, RRID: 
MGI:5657312) and GPR37 knock out (KO, stock no: 
005806) male mice (B6.129P2- GPR37tm1Dgen/J; Jackson 
Laboratory, Bar Harbor, ME, USA) were used for analyzing 
GPR37 species in various brain regions. The University of 
Barcelona Committee on Animal Use and Care approved 
the protocol (no: 7085). Animals were housed and tested in 
compliance with the European Union directives (2010/63/
EU), FELASA, and ARRIVE guidelines. The animals were 
euthanized by cervical dislocation and the fresh brain regions 
(cortex, striatum, hippocampus, and cerebellum) were used 
for membrane preparation immediately after harvesting. 
Samples from cortex, hippocampus and cerebellum of four 
Adam10 conditional KO (cKO) mice (Adam10f/f; CamKIIα- 
Cre)30 and three Cre- negative Adam10F/F or Adam10F/+ WT 
littermate controls harvested at postnatal day 20 were pro-
vided by Prof. Paul Saftig.
2.3 | DNA constructs
The N- terminally Myc- tagged and C- terminally FLAG- tagged 
hGPR37 with a cleavable HA signal peptide in pFT- SMMF 
and the C- terminally FLAG- tagged mGPR37 in pcDNA3 
have been described previously.16 Constructs with mutations 
or with short deletions were generated using the QuikChange 
Lightning mutagenesis kit (Agilent Technologies, Santa Clara, 
CA, USA) and Myc- hGPR37- FLAG as a template. The fol-
lowing oligonucleotides and corresponding reverse comple-
ments were used: CCCAGGCGTCCGCGCCGCGGCGCTG 
(R54A), GGTCCCCAGGCGTCCGCGCCGGCGGCCTGG 
ATCACTGTAGG (R51;52;54A), GGTCCCCAGGCGTCC 
TGGATCACTGTAG (∆R51- R54), GCCCCCTGCTCCTC 
CAGAACGTCTCTTG (∆R68- R73), and GGCTCCTGACC 
CCAGGGGCCAGG (∆R121- R126). The hADAM10 
E384A construct was prepared in a similar manner using the 
oligonucleotide and the corresponding reverse complement 
CTCACATTACTTTTGCTCACGCAGTTGGACATAACT 
TTGGATCC and the WT HA- tagged hADAM10 in 
pEAK1231 (from Prof. Mikko Hiltunen, University of Eastern 
Finland, Kuopio, Finland) as a template. The hGPR37 tagged 
at its N- terminus with NanoLuc and HA was prepared as de-
scribed previously.18 The prepared constructs were verified 
by DNA sequencing.
2.4 | Cell culture and transfections
The stably transfected tetracycline- inducible HEK293i cell 
line expressing Myc- hGPR37- FLAG was prepared using 
Invitrogen's T- REx System, as described.16 Briefly, the re-
ceptor construct and pOG44 plasmid were co- transfected 
into the Tet repressor expressing HEK293i cells under 
blasticidin S (4 µg/mL, InvivoGen, Toulouse, France) and 
hygromycin (400 µg/mL, InvivoGen) selection. The furin- 
deficient human colon carcinoma LoVo cells32 were ob-
tained from Sigma- Aldrich. ADAM10KO, ADAM17KO, 
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and the parental HEK293T cells were a kind gift from 
Prof. Christoph Garbers (Otto- von- Guericke- University 
Magdeburg, Magdeburg, Germany),33 and SH- SY5Y cells 
from Prof. Mikko Hiltunen (University of Eastern Finland, 
Kuopio, Finland). The ADAM10KO and the parental WT 
mouse embryonic fibroblast (MEF) cells have been de-
scribed previously.34
All cell lines were maintained at 37 ºC in a humidified 
atmosphere of 5% CO2. HEK293, MEF and SH- SY5Y 
cells were cultured in DMEM and LoVo cells in Ham's 
F- 12 containing 10% FBS. The media were supplemented 
with 100 units/mL penicillin and 0.1 mg/mL streptomycin 
as well as with selection antibiotics in the case of the sta-
bly transfected HEK293i cells. Receptor expression was in-
duced in HEK293i cells by adding 0.5 μg/mL tetracycline 
to the fresh culture medium in the absence of selection an-
tibiotics. For transient transfections, cells were transfected 
at 60- 80% confluency with linear 25- kDa polyethylenei-
mine (Polysciences, Warrington, PA, USA), Lipofectamine 
3000 (Invitrogen), or jetOPTIMUS (Polyplus- transfection, 
Illkirch, France). All transfection reagents were used at 1:3 
or 1:1 DNA- to- reagent ratio. The cells were transfected 
with 0.75- 2  μg (6- cm plate) or 2- 5  μg (10- cm plate) of 
receptor DNA and harvested after 24- 48  hours. For co- 
transfections, GPR37 and ADAM10 plasmids were used at 
1:1 ratio. Protease inhibitors, when used, were added to the 
culture medium 4 hours or 1 hour after starting the trans-
fection or induction.
2.5 | Small interfering RNA- mediated 
gene silencing
For siRNA- mediated knock- down of ADAM10 and 
ADAM17, stable HEK293i cells at 20% confluency were 
transfected with Lipofectamine RNAiMAX (Invitrogen) 
using 20  nM siGENOME SMART pool against ADAM10 
or ADAM17 and siGENOME non- targeting siRNA pool 
for control cells (Dharmacon, Lafayette, CO, USA) in Opti- 
MEM medium (Invitrogen) containing 4% FBS. Medium was 
changed to DMEM containing FBS, penicillin, and strepto-
mycin 24 hours after transfection, and after 42 hours the cells 
were induced to express the receptor for 6 hours.
2.6 | Metabolic pulse- chase labeling and cell 
surface biotinylation
Stably transfected HEK293i cells in 25- cm
2 flasks were in-
duced to express GPR37 for 6- 16  hours and subjected to 
metabolic labeling with 70- 100  μCi/mL [35S]- methionine/
cysteine (PerkinElmer, Waltham, MA, USA) as described 
previously.35 GI254023X and decCMK were added to the de-
pletion medium and were maintained thereafter. At the end of 
the chase, cell surface proteins were biotinylated with 0.5 mg/
mL EZ- Link™ sulfo- NHS- Biotin (Thermo Fisher Scientific), 
as described.36
2.7 | Preparation of cellular membranes and 
whole- cell extracts
Total cellular lysates and cellular membranes from cul-
tured cells were prepared as described.37 The membrane 
homogenization buffer (25 mM Tris- HCl, pH 7.4, 20 mM N- 
ethylmaleimide) contained a protease inhibitor mix: EDTA 
(2 mM), 1,10- phenanthroline (2 mM), phenylmethylsulfonyl 
fluoride (0.5 mM), leupeptin (5 µg/mL), soybean trypsin in-
hibitor (5 µg/mL) and benzamidine (10 µg/mL). For mem-
brane solubilization and preparation of cellular lysates, the 
homogenization buffer was supplemented with 0.5% n- 
dodecyl- β- D- maltoside (Enzo Life Sciences) or Triton X- 100 
and 140 mM NaCl. N- ethylmaleimide was omitted from the 
membrane solubilization buffer. Membrane preparation from 
mouse brain tissue samples was performed by suspending the 
samples in 50 mM Tris- HCl, pH 7.4 containing the protease 
inhibitor mix and homogenizing with the VDI12 homoge-
nizer (VWR International, Darmstadt, Germany) three times 
for 10 seconds at 800 rpm on ice. Tissue homogenates were 
centrifuged at 12 000× g for 30 minutes and the membrane 
pellets were resuspended in the homogenization buffer be-
fore adding SDS- sample buffer. Protein concentrations were 
determined using either Bio- Rad (Hercules, CA, USA) DC or 
Pierce (Thermo Fisher Scientific) BCA protein assays with 
BSA as a standard.
2.8 | Receptor purification
Receptors were purified with FLAG M2 or cMyc antibody 
resins, and ADAM10 with the HA antibody resin (all from 
Sigma- Aldrich). One- step receptor immunoprecipitation was 
performed before Western blotting and two- step purification 
before fluorography of [35S]- methionine/cysteine- labeled re-
ceptors following previously described protocols.36 For the 
in vitro ADAM10 cleavage assay, protease inhibitors were 
omitted during the second immunoprecipitation step, exclud-
ing leupeptin. Biotinylated receptors were first purified with 
streptavidin agarose (Thermo Fisher Scientific) and then im-
munoprecipitated with FLAG M2 antibody as described.36 
The purified receptors were eluted from the resins with 
SDS- sample buffer for direct analysis by SDS- PAGE or with 
1% SDS, 50  mM Na- phosphate, pH 5.5 before enzymatic 
deglycosylation.
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2.9 | Deglycosylation
The purified receptors were deglycosylated with 50 mU/mL 
endoglycosidase H (Endo H) and 20- 30  U/mL peptide- N- 
glycosidase F (PNGase F, Sigma- Aldrich), as described.35 
Membranes prepared from the mouse striatum were deglyco-
sylated with Endo H and PNGase F using reagents from New 
England Biolabs (Ipswich, MA, USA) according to the pro-
tocol provided by the manufacturer. Briefly, 50 µg of protein 
was treated with denaturing buffer at 100°C for 10 minutes. 
After adding the glycobuffer and enzymes (15  U/mL), the 
samples were incubated at 37°C for 1 hour.
2.10 | In vitro cleavage assay with 
recombinant ADAM10
The purified hGPR37 was cleaved with rADAM10 while 
still attached to the FLAG antibody resin. Before the assay, 
the resin was washed with the incubation buffer (0.1% Triton 
X- 100, 25  mM Tris- HCl, pH 7.4, 100  mM NaCl, 1  mM 
CaCl2, 2.5 mM ZnCl2) and the samples were incubated with 
rADAM10 (10 µg/mL) as specified in Figure 4. The reaction 
was stopped by adding 10 mM EDTA in 0.1% Triton X- 100, 
25 mM Tris- HCl, pH 7.4, 140 mM NaCl, 0.2 mM phenyl-
methylsulfonyl fluoride, 2  mM 1,10- phenantroline, 5  µg/
mL leupeptin, 5 µg/mL soybean trypsin inhibitor and 10 µg/
mL benzamidine. After washing the resin, the receptor was 
eluted with an SDS- sample buffer.
2.11 | Purification of the shed N- terminal 
receptor fragment
For Figures 1 and 3, the N- terminal receptor fragment was 
immunoprecipitated and analyzed using Tris- Tricine gel 
electrophoresis as described previously.16 For Figure  7, 
the cells were transiently transfected with NanoLuc- HA- 
hGPR37 on 6- cm plates and Myc- hGPR37- FLAG on 10- cm 
plates for 16 hours and treated with decCMK and GI254023X 
for 12  hours in serum- free medium. The conditioned me-
dium was then collected and concentrated to 500 µL using 
the Amicon Ultra- 15 10K centrifugal filter devices (Merck 
Millipore). Aliquots (25  µL) of the concentrated samples 
were diluted 1:1 with SDS sample buffer and separated on 
12% SDS- PAGE gels.
F I G U R E  1  Nonselective and ADAM10- selective metalloprotease inhibitors increase the amount of full- length hGPR37 at the cell surface. 
A, Schematic model of hGPR37 with the metalloprotease cleavage site at Glu167↓Gln16816 and with three N- glycosylation sites16 shown as blue 
glycan structures. The added Myc and FLAG epitope tags are also indicated. B, HEK293i cells stably transfected with Myc- hGPR37- FLAG were 
induced to express the receptor for 24 hours and treated for the last 23 hours with the indicated metalloprotease inhibitors (20 µM marimastat, 
2 µM GI254023X) or vehicle. Cells were fixed, permeabilized, and stained with the indicated antibodies followed by Alexa- Fluor- 488- and - 568- 
conjugated secondary antibodies. The nuclei were stained with TO- PRO- 3 iodine. The cellular localization of cMyc antibody- labeled full- length 
receptors was analyzed by confocal microscopy. Scale bars: 10 µm. C, Induced HEK293i cells were treated with the indicated concentrations 
of GI254023X for 23 hours and analyzed by flow cytometry after labeling cell surface receptors with cMyc antibody and the phycoerythrin- 
conjugated secondary antibody. The results represent five independent experiments performed with triplicate samples. The fluorescence intensity 
values were normalized to the mean value obtained from cells treated with vehicle only. The results were analyzed before normalization using 
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2.12 | SDS- PAGE, Western blotting, and 
fluorography
Protein samples were reduced with 50 mM DTT for 2- 5 min-
utes at 95°C and separated by SDS- PAGE using reagents 
and equipment from the Bio- Rad Laboratories. Proteins were 
transferred to 0.45 µm polyvinylidene difluoride membranes 
(Immobilon- P, Merck Millipore) using the Mini Trans- Blot 
cell apparatus or a semidry transfer system (Trans- Blot SD 
or Trans- Blot Turbo). The membranes were blocked with 5% 
nonfat dry milk in TBS- T (25 mM Tris- HCl, pH 7.4, 150 mM 
NaCl, 0.1% Tween- 20) or PBS- T (2 mM KH2PO4, 137 mM 
NaCl, 2.7 mM KCl, pH 7.2, 0.05% Tween- 20; Figures 8- 9 
and S5- S6) and probed with the appropriate antibodies in 
F I G U R E  2  ADAM10 selective inhibitor GI254023X inhibits N- terminal cleavage of human and mouse GPR37. Stably transfected HEK293i 
cells were induced to express Myc- hGPR37- FLAG (A, C, G, H) or, alternatively, mGPR37- FLAG and Myc- hGPR37- FLAG were transiently 
expressed in either SH- SY5Y (E) or HEK293 (F) cells for 24 hours. The cells were treated with the indicated concentrations of protease inhibitors 
or vehicle for 20- 23 hours. The shed N- terminal receptor fragment from the conditioned culture medium (A) and membrane- bound receptors from 
cellular lysates (C, E- H) were immunoprecipitated and analyzed by SDS- PAGE and Western blotting. The outlined area in panel E is shown with 
a longer exposure time. The identified hGPR37 species are depicted in panel B. The 67- kDa precursor and the 96- kDa full- length mature receptor 
are indicated with closed and open circles, respectively. The shed 32- 35- kDa N- terminal receptor fragment is indicated with a closed triangle and 
the 53- and 34- kDa cleaved C- terminal fragments with open and closed squares, respectively. The 70- kDa receptor species are indicated with an 
open triangle. Arrows in panel C indicate receptor oligomers and higher molecular mass aggregates. Panel D shows relative changes in the intensity 
of the 96- kDa full- length and 53- kDa cleaved receptors seen in panel C (left and right panels, respectively). The values were normalized to the 
67- kDa precursor and are shown as means ± SD from four to nine independent experiments. The repeated- measures one- way ANOVA followed 
by Dunnett's multiple comparison test was used for the statistical comparison. **P < .01; *P < .05; ns, nonsignificant. Ab, antibody, decCMK, 
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TBS/0.1% BSA or PBS- T/5% nonfat dry milk. The Luminata 
Crescendo Western HRP substrate (Merck Millipore) was 
used to reveal the specific protein bands on the membranes 
that were analyzed by digital imaging with the Odyssey 
FC imager (LI- COR Biosciences, Lincoln, NE, USA) or 
Amersham Imager 600 (GE Healthcare). Alternatively, the 
membranes were exposed on UltraCruz™ autoradiography 
film (SantaCruz Biotechnology). Gels containing radiola-
beled samples were treated for fluorography as described36 
and exposed on Kodak Biomax MR film (Sigma- Aldrich). 
The relative intensities of bands on films were analyzed by 
densitometric scanning with the Umax PowerLook 1120 
color scanner (Umax Technologies, Dallas, TX, USA) and 
the Image Master 2D Platinum 6.0 software (GE Healthcare, 
Chicago, IL, USA). The results were quantified using the LI- 
COR Image studio v. 5.2, subtracting the local background 
from each lane.
2.13 | Flow cytometry
The total pool of full- length cell surface receptors was ana-
lyzed using mouse mAb cMyc (9E10, 3  μg/mL, 626802; 
BioLegend) and phycoerythrin- conjugated rat anti- mouse 
IgG1 (2  μg/mL, 550  083; BD Biosciences, Franklin Lakes, 
NJ, USA) as described.38 Induced HEK293i cells were used 
in parallel for flow cytometry and Western blot analyses for 
Figures 1C and 2B, and for Figures 3A,D, respectively. For 
Figure 7C, HEK293 cells were transiently transfected with 5 µg 
of Myc- hGPR37- FLAG or Myc- hGPR37(∆51- 54)- FLAG on 
10- cm plates. Cells were reseeded onto 6- well plates 4 hours 
after transfection and treated with decCMK and GI254023X 
for 19 hours. A total of 10 000 cells from each sample were 
analyzed with the FACSCalibur flow cytometer and the 
CellQuestPro 6.0 software (BD Biosciences) (Figures 1 and 3). 
Alternatively, the ACCURI C6 flow cytometer and FlowJo 
F I G U R E  3  ADAM10 downregulation in HEK293 cells inhibits hGPR37 ectodomain cleavage and shedding. Inducible HEK293i cells were 
treated with siRNA pools targeting ADAM10 or ADAM17 or with the control siRNA pool for 72 hours and were induced to express hGPR37 
for 8 hours at the end of the siRNA transfection. A, Receptors from solubilized cellular membranes were analyzed by SDS- PAGE and Western 
blotting. The knock- down of ADAM10 and ADAM17 was confirmed with the corresponding selective antibodies. The translocon- associated 
protein α- subunit (TRAPα) was used as a loading control. B, N- terminal receptor fragments in the cell culture medium were immunoprecipitated 
and analyzed by Western blotting with cMyc antibody. D, Cell surface cMyc antibody labeled receptors from five independent experiments were 
analyzed in triplicate by flow cytometry. Relative changes in the 96- kDa full- length and 53- kDa cleaved receptors seen in panel A are shown in 
panel C as means ± SD from 4- 5 independent experiments. The values were normalized to the loading control before statistical analysis. The data 
were analyzed by repeated measures one- way ANOVA and Dunnett's multiple comparison test. *P < .05; ns, nonsignificant. The abbreviations and 
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V10 software (BD Biosciences) were used for measurements 
and data analysis (Figure 7). The background fluorescence of 
live cells stained only with the secondary antibody was sub-
tracted from the mean fluorescence of live cells stained with 
the cMyc and secondary antibodies.
2.14 | Confocal microscopy
HEK293i cells expressing Myc- hGPR37- FLAG were cul-
tured, fixed, and permeabilized as described elsewhere,16 
and stained with the appropriate antibodies.39 The nuclei 
were stained with TO- PRO- 3 iodine (2 µM, Invitrogen) for 
10 minutes and the fluorescence was detected with the Zeiss 
LSM780 laser scanning confocal microscope (Carl Zeiss 
Microscopy, Jena, Germany), using the Plan- Apochromat 
63x1.4 numerical aperture oil- immersion objective. The con-
focal images were processed with the Zen lite 2012 and Zen 
2012 black edition software (Carl Zeiss Microscopy).
2.15 | Sequence alignment
The sequence logo of the GPR37 N- terminus corresponding to 
hGPR37 amino acids 27- 178 was generated using WebLogo40 
(http://weblo go.three pluso ne.com/). The respective sequences 
F I G U R E  4  N- terminal cleavage of GPR37 is impaired in MEF and HEK293T cells lacking ADAM10 and is induced in vitro with rADAM10. 
The Myc- and FLAG- tagged hGPR37 was transiently expressed for 24 hours in WT and ADAM10KO MEF cells (A) or in WT, ADAM10KO, 
and ADAM17KO HEK293T cells that were treated or not with marimastat for 20 hours (B). For C- D, WT and ADAM10KO HEK293T cells were 
transiently transfected with Myc- hGPR37- FLAG together with the HA- tagged WT hADAM10 or its inactive E384A mutant (1:1 DNA ratio) for 
48 hours. For E, mGPR37- FLAG was transiently expressed for 24 hours in WT and ADAM10KO HEK293T cells treated or not with marimastat 
for 20 hours, and for F, hGPR37 was expressed for 24 hours in stably transfected HEK293i cells treated with decCMK (10 µM) and GI254023X 
(5 µM) for 20 hours. Receptors and ADAM10 were immunoprecipitated from cellular lysates with FLAG and HA- antibodies, respectively, 
before analysis by Western blotting. For F, receptors were treated before elution from the FLAG antibody resin with rADAM10 as indicated. The 
additional GPR37 C- terminal fragment seen in HEK293T cells is indicated with an arrowhead (B, E). The other symbols and abbreviations are 
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of fourteen placental mammals (Table  S1) were aligned 
using CLUSTAL Omega (1.2.4) and submitted to Weblogo 
for the generation of graphic representation. CLUSTAL 
Omega multiple sequence alignment was also performed for 
the first 300 and 278 amino acids of hGPR37 and mGPR37, 
respectively.
2.16 | Data analysis
The data were analyzed with the GraphPad Prism 8.3 software 
(GraphPad Software, La Jolla, CA, USA). Statistical analy-
ses were performed using unpaired t- test or repeated meas-
ures one- way or two- way ANOVA followed by Dunnett's or 
Tukey's multiple comparison test. The limit of significance 
was set at P < .05.
3 |  RESULTS
3.1 | N- terminal cleavage of GPR37 
is inhibited by the ADAM10- selective 
metalloprotease inhibitor GI254023X
To initiate identification of the protease(s) involved in 
GPR37 processing, we first tested the ability of broad- 
spectrum and selective metalloprotease inhibitors to inhibit 
cleavage of the Myc- and FLAG- epitope tagged receptor 
(Figure  1A) in stably transfected inducible HEK293i cells. 
The subcellular localization of cMyc antibody- stained full- 
length receptors was analyzed by confocal microscopy after 
24- hour induction of receptor expression. Treatment with the 
broad- spectrum inhibitor marimastat increased the number 
of full- length receptors at the cell surface observed as en-
hanced co- localization with the plasma membrane marker 
Na+/K+- ATPase (Figure 1B). Similar results were obtained 
with GI254023X (Figure  1B), an inhibitor selective for 
ADAM10.41 Likewise, the amount of cMyc- stained full- 
length receptors detected at the plasma membrane by flow 
cytometry was elevated (Figure 1C). This effect was depend-
ent on the inhibitor concentration used, with a significant in-
crease detected already at 0.25 µM GI254023X.
We then investigated the effect of GI254023X on re-
ceptor cleavage by analyzing membrane- bound and shed 
receptor fragments by Western blotting. Under steady- state 
conditions, an N- terminal fragment of about 32- 35 kDa was 
purified with cMyc antibody from the conditioned culture 
medium of induced HEK293i cells (Figure  2A, first lane; 
Figure  2B). The same antibody also detected two specific 
full- length receptor species of about 67 and 96  kDa from 
cellular lysates following immunoprecipitation with FLAG 
antibody (Figure  2C, left panel, first lane, Figure  S1). As 
demonstrated earlier,16 these species represent intracellular 
receptor precursors and mature plasma membrane receptors, 
respectively (Figure 2B). Immunoblotting of these samples 
with FLAG antibody revealed a prominent C- terminal re-
ceptor fragment of about 53  kDa and a minor 34- kDa one 
in addition to the 67- kDa precursor (Figure 2C, right panel, 
first lane, Figure  S1). While the 53- kDa form represents 
GPR37 that is cleaved between Glu167 and Gln168 at the 
receptor N- terminal ectodomain, the 34- kDa species is most 
likely cleaved adjacent to the first transmembrane domain16 
(Figure  2B). The mature 96- kDa receptor, however, was 
poorly recognized with FLAG antibody and was typically not 
seen (Figure 2C, right panel, first lane; Figures S1 and S2).
As expected, treatment with GI254023X resulted in a 
significant concentration- dependent increase in the 96- kDa 
full- length receptor and a corresponding decrease in the 53- 
kDa cleaved form (Figure  2C,D) and the shed 32- 35- kDa 
fragment (Figure 2A). No changes were seen for the 34- kDa 
cleaved form (Figure 2C, right panel). Similar findings were 
obtained when hGPR37 and mGPR37 were transiently ex-
pressed in metalloprotease inhibitor- treated human neuro-
blastoma SH- SY5Y cells and in HEK293 cells, respectively 
(Figure  2E,F). These results suggest that the metalloprote-
ase mediated GPR37 ectodomain cleavage is neither a cell 
line nor species- specific event. Interestingly, the major C- 
terminal receptor fragment identified for mGPR37 migrated 
slower in SDS- PAGE than the corresponding human receptor 
species (Figure 2F). The difference remained after removing 
N- glycans with PNGase F (Figure S3), suggesting nonidenti-
cal metalloprotease cleavage sites for the two receptors.
Intriguingly, treatment of stably transfected HEK293i cells 
with GI254023X resulted in the appearance of an additional 
hGPR37 form on Western blots that was not normally seen. 
This species that appeared either as a distinct species of about 
70 kDa or as an ill- defined smear above the 67- kDa receptor 
precursor (hereafter called the 70- kDa receptor species) was 
detected with FLAG antibody, but not with cMyc antibody 
(Figure 2C, right panel; B). This receptor form was likewise 
detected when cells were treated with broad- spectrum metal-
loprotease inhibitors, such as GM6001, TAPI- 1, or marimas-
tat, but not with inactive GM6001 or inhibitors against other 
protease families (Figure 2G). In addition to the FLAG an-
tibody, a GPR37 N- terminal antibody raised against amino 
acids 27- 265 of hGPR37,29 was also able to detect the 70- kDa 
form (Figure 2H). Thus, the ectodomain of hGPR37 must be 
proteolytically processed at yet another site that is located up-
stream of the identified metalloprotease cleavage site.
3.2 | The N- terminal ectodomain of GPR37 
is cleaved by ADAM10
The ability of GI254023X to inhibit hGPR37 N- terminal cleav-
age and shedding at low concentrations suggests that cleavage 
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at the identified Glu167↓Gln168 site is mediated by ADAM10. 
To investigate this possibility further, we utilized siRNA- 
mediated knock- down of ADAM10 and ADAM17, another 
metalloprotease commonly involved in ectodomain shedding,26 
in HEK293i cells stably expressing hGPR37. The knock- down 
of the desired enzymes was verified by subjecting detergent- 
solubilized membrane fractions to Western blotting with selec-
tive antibodies against ADAM10 and ADAM17 (Figure 3A). 
Analysis of the solubilized receptors with the hGPR37 N- 
terminal antibody revealed that knock- down of ADAM10, but 
not ADAM17, increased the amount of the full- length recep-
tor significantly (Figure 3A,C). Correspondingly, the amount 
of the cleaved receptor species, detected with an antibody 
against the GPR37 C- terminus,5 was decreased (Figure 3A,C). 
Likewise, the amount of the shed N- terminal fragment in the 
culture medium was reduced when the cells were treated with 
the ADAM10 siRNA pool (Figure 3B). These results were fur-
ther supported by flow cytometry as knock- down of ADAM10, 
but not ADAM17, significantly increased the number of full- 
length receptors at the cell surface (Figure 3D).
Further evidence for the role of ADAM10 in GPR37 cleavage 
was acquired by expressing the receptor in stable cell lines that 
lack ADAM10. As expected, transient expression of hGPR37 
in ADAM10 deficient MEF cells34 showed that the full- length 
mature 96- kDa species was substantially increased and the 53- 
kDa cleaved form decreased compared with the corresponding 
WT cells (Figure 4A). These results were reproduced by em-
ploying ADAM10 deficient HEK293T cells generated using 
CRISPR/Cas9- mediated genome editing, but not by using the 
corresponding ADAM17 deficient cells33 (Figure 4B). The full- 
length receptor in the ADAM10KO and ADAM17KO cells was 
slightly smaller in size compared to the WT cells (Figure 4B), 
most likely due to somewhat altered receptor glycosylation in 
the KO cells (Figure S4).
Next, to test whether we could rescue the enzymatic activ-
ity of ADAM10, we co- transfected hGPR37 either with the 
HA- tagged WT or an inactive Glu384Ala mutant ADAM1042 
in ADAM10KO HEK293T cells. Both WT and mutant 
ADAM10 were expressed as two forms, the larger immature 
and the smaller mature species42 (Figure 4C). The abundance 
of the full- length mature receptor was decreased when cells 
were co- transfected with the WT ADAM10 (Figure 4D). This 
was accompanied by a corresponding dramatic increase in 
the cleaved 53- kDa receptor (Figure 4D). In contrast, over-
expression of the inactive mutant ADAM10 had no effect 
(Figure 4D). We also transfected the WT and ADAM10KO 
HEK293T cells with mGPR37. As expected, cleavage of the 
receptor was reduced in KO cells and this inhibitory effect 
was further enhanced when cells were treated with marimas-
tat (Figure 4E). Finally, we subjected the purified hGPR37 
to rADAM10- mediated cleavage in vitro, and as anticipated, 
the enzyme cleaved the receptor in a time- dependent manner 
at 37°C (Figure 4F). Taken together, these results imply that 
the major enzyme responsible for cleaving GPR37 is indeed 
ADAM10. Nevertheless, we cannot exclude the possibil-
ity that other metalloproteases are also involved in GPR37 
processing, especially in cells lacking ADAM10. This was 
suggested by the finding that an additional smaller- sized C- 
terminal receptor fragment seen in HEK293T cells was re-
sponsive to marimastat treatment (Figure 4B,E).
3.3 | The GPR37 ectodomain is cleaved at 
an additional N- terminal site
The 70- kDa hGPR37 species detected in metalloprotease 
inhibitor- treated cells indicates that the receptor ectodo-
main is cleaved at an additional site upstream of the iden-
tified ADAM10 site. Furthermore, this additional cleavage 
appears to be mediated by a protease not belonging to the 
metalloprotease family as it was detected in the presence of 
broad- spectrum metalloprotease inhibitors (see Figure 2G). 
The appearance and identity of the 70- kDa receptor spe-
cies were first studied by metabolic pulse- chase labeling 
and cell surface biotinylation. Under control conditions, the 
67- kDa receptor precursor was rapidly converted to the 96- 
kDa mature full- length receptor that was then cleaved to the 
53- kDa proteolytically processed form and to the less abun-
dant 34- kDa species (Figure  5A, upper panel). When cells 
were treated with GI254023X during depletion, pulse, and 
chase, the appearance of the cleaved 53- kDa form was inhib-
ited (Figure 5A). This was, however, less evident than was 
normally seen in Western blot experiments, most likely due 
to the shorter treatment time with the inhibitor. The 70- kDa 
receptor form became apparent during the chase and was 
clearly detectable after 3  hours (Figure  5A). Importantly, 
this receptor species was detected at the cell surface together 
with the 96- kDa full- length and the 53- kDa cleaved receptor 
(Figure 5A, lower panel). Enzymatic deglycosylation of the 2- 
hour chase samples from cells treated or not with GI254023X 
revealed that the 70- kDa species was insensitive to Endo H 
(Figure  5B) that digests N- glycans typical to endoplasmic 
reticulum- localized proteins. However, upon treatment with 
PNGase F, which releases also fully processed N- glycans, it 
was deglycosylated to a slightly smaller size than the degly-
cosylated receptor precursor (Figure 5B). Thus, the 70- kDa 
receptor form represents a mature cell surface receptor that 
has been cleaved at a site close to the extreme end of the 
N- terminus but downstream of the N- glycosylation site at 
Asn36 (see Figure 2B).
To determine the protease responsible for the conversion 
of hGPR37 to the 70- kDa species, we first tested the abil-
ity of various protease inhibitors to inhibit this cleavage step 
in HEK293i cells treated simultaneously with marimastat 
(Figure 5C). No differences in the amount of the 70- kDa spe-
cies or the full- length 96- kDa form were detected with protease 
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inhibitors belonging to serine- , cysteine- , trypsin- , aspartyl- or 
metallo- endopeptidase families (Figure 5C). In contrast, treat-
ment with the PC inhibitor decCMK resulted in a clear in-
crease in the full- length GPR37 while the 70- kDa species was 
no longer apparent (Figure 5C). These changes, however, were 
not observed with the corresponding membrane- impermeable 
inhibitor hexa- D- arginine (Figure 5C). Metabolically labeled 
cells chased for 2  hours and treated with decCMK without 
the metalloprotease inhibitor showed a similar increase in the 
full- length GPR37, but not in the 70- kDa species (Figure 5D). 
Treatment with the metalloprotease inhibitor GM6001, in con-
trast, led to an increased abundance of both the 70- kDa form 
and the full- length receptor (Figure 5D). Since decCMK is se-
lective for furin and furin- like PCs, these data imply that GPR37 
is cleaved by member(s) of this protease family. Furthermore, 
this cleavage step appears to take place intracellularly before 
the receptor reaches the cell surface or, alternatively, after 
endocytosis, as only the membrane- permeable inhibitor was 
able to reduce the cleavage. Interestingly, the two tested cys-
teine protease inhibitors, leupeptin and E- 64d, increased the 
amount of the 34- kDa C- terminal receptor fragment that was 
not responsive to metalloproteinase inhibitors (Figure 5C, see 
also Figure 2C,G). Thus, this species most likely represents a 
receptor degradation intermediate in the endosomal pathway.
3.4 | GPR37 is cleaved by furin at a 
conserved Arg54↓Asp55 site in the N- terminus
Furin, together with other basic amino acid- specific PCs, 
possesses a strong preference for the cleavage motif (Arg/
Lys)- 2nX- Arg↓ (where n  =  0- 3 aa).24 The N- terminal do-
main of hGPR37 contains four potential sites upstream of the 
Glu167↓Gln168 cleavage site that fit these criteria. These po-
tential sites are well conserved according to a sequence logo 
generated from N- terminal GPR37 sequences of 14 placental 
mammals (Figure 6).
To test if any of these sites are used, we created constructs 
with short deletions at the putative sites and transiently 
expressed them in HEK293 cells. The site closest to the 
F I G U R E  5  GPR37 is cleaved in its N- terminal domain by a non- metalloprotease. A, B and D, HEK293i cells were induced to express 
hGPR37 for 6 hours (A, B) or 16 hours (D), labeled with [35S]methionine/cysteine for 30 minutes and chased for various time periods before cell 
surface proteins were biotinylated (A) or not (B, D) with sulfo- NHS- biotin. GI254023X, decCMK, or vehicle were added to the medium during 
depletion, labeling, and chase. Receptors were subjected to two- step immunoprecipitation with FLAG antibody (A, upper panel, B, D) or were first 
purified with streptavidin agarose and then with FLAG antibody (A, lower panel) before analysis by SDS- PAGE and fluorography. For panel B, 
immunoprecipitated receptors from 120- minute chase samples were deglycosylated with Endo H (50 mU/mL) or PNGase F (20 U/mL) before SDS- 
PAGE. C, HEK293i cells were induced for 24 hours and treated with the indicated protease inhibitors or vehicle for 20 hours. Immunoprecipitated 
receptors were analyzed by SDS- PAGE and Western blotting. Note that GI254023X inhibits receptor cleavage more efficiently at 5 µM (B) than at 
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Glu167↓Gln168 cleavage site was omitted from the analysis 
as it is located only about 10 amino acids upstream of the 
metalloprotease cleavage site. Deletion of the most distal site 
at the receptor N- terminus (Δ51- 54) increased the abundance 
of the full- length receptor and abolished the cleavage step that 
produces the 70- kDa receptor species in GI254023X- treated 
WT receptor- expressing cells (Figure 7A). No clear effect was 
observed when the two other putative cleavage sites (Δ68- 
73 and Δ121- 126) were deleted (Figure 7A). Similar results 
were obtained when the three arginine residues at positions 
51, 52, and 54 or only the arginine residue 54 preceding the 
expected cleavage site were mutated to alanine (Figure 7B). 
These results indicate that PC(s) cleave the GPR37 ecto-
domain at a highly conserved site at Arg54↓Asp55. Further 
evidence for this finding was provided by flow cytometric 
analysis of cells transiently transfected with the WT and ∆51- 
54 mutant GPR37 (Figure  7C). The number of full- length 
WT, but not mutant receptors, was increased significantly at 
the cell surface when cells were treated simultaneously with 
decCMK and GI254023X compared to cells treated only with 
the metalloprotease inhibitor (Figure 7C).
To test if inhibition of the PC- mediated cleavage also af-
fects the shed N- terminal receptor fragment, we treated tran-
siently transfected HEK293 cells with decCMK, GI254023X, 
or both inhibitors simultaneously, and analyzed the shed frag-
ments in the concentrated conditioned medium by Western 
blotting. As expected, the amount of the receptor fragment 
detected with the N- terminal antibody was decreased with 
GI254023X (Figure  7D). In contrast, its abundance was 
increased with decCMK but only when the cells were not 
treated simultaneously with GI254023 (Figure  7D). This 
observation, together with the fact that the fragment could 
also be detected with cMyc antibody that recognizes the N- 
terminal Myc tag (see Figures  2A and 3B), implies that it 
originates from receptors that are cleaved by ADAM10 but 
not by PC(s). Similar results were obtained when the cells 
were transfected with hGPR37 carrying N- terminal NanoLuc 
and HA tags (Figure 7E), indicating that the added tags do no 
alter proteolytic processing and shedding of the receptor ect-
odomain. Altogether, these results imply that the ADAM10- 
mediated receptor cleavage occurs efficiently, whereas the 
cleavage by PC(s) is inefficient.
Finally, to further identify the enzyme that cleaves 
hGPR37 at the Arg54↓Asp55 site, we expressed the recep-
tor in furin- deficient human colon carcinoma LoVo cells32 
(Figure 7F). Both marimastat and GI254023X were able to 
inhibit receptor cleavage at the Glu167↓Gln168 site in these 
cells (Figure 7F). However, the 70- kDa species was not de-
tected (Figure 7F), although it was clearly visible in HEK293 
cells tested in parallel (data not shown). These results are in 
line with the notion that the major PC involved in GPR37 
processing at the Arg54↓Asp55 site is furin.
3.5 | Processing of GPR37 
in the mouse brain occurs in an ADAM10- 
dependent manner
The finding that both human and mouse GPR37 undergo 
ADAM10- mediated cleavage in cultured cells prompted us 
to investigate the processing of the receptor in a more physi-
ologically relevant environment. To this end, membrane frac-
tions were prepared from various brain regions of GPR37KO 
mice and corresponding WT animals and expressed GPR37 
species were studied by Western blotting using antibodies 
against the receptor N- and C- terminal domains. As reported 
earlier,5 a specific receptor species of about 62 kDa was de-
tected with the N- terminal antibody from the cerebellum, cor-
tex, hippocampus, and striatum of GPR37WT, but not from 
KO animals (Figure 8). This species was sensitive to digestion 
with PNGase F but not with Endo H (Figure S5), thus rep-
resenting a mature receptor with fully processed N- glycans. 
F I G U R E  6  Conservation of GPR37 N- terminal tail. WebLogo40 
was used to generate a graphical representation of conservation 
between fourteen placental mammalian species (see Table S1). The 
generated sequence logo corresponding to residues 27- 178 of hGPR37 
(shown as a gray bar below the schematic model of the N- terminal 
domain) displays the conservation of each residue, indicated by the 
overall height of the letter. The relative height of each letter in the 
stack indicates the frequency of the corresponding amino acid at the 
site. The positively charged amino acids Arg and Lys are shown in red. 
The consensus sequence for N- glycosylation and putative PC cleavage 
sites are indicated with blue and yellow bars, respectively, below 
the sequence. The metalloprotease cleavage site (Glu167↓Gln168) 
identified for hGPR3716 is indicated with the red scissors. The 
corresponding sites for hGPR37 are also shown in the schematic model
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In comparison, the C- terminal antibody detected a distinct 
smaller receptor form with an apparent molecular weight of 
about 42 kDa in the same samples. For an unknown reason it 
was not able to detect the 62 kDa species (Figure 8). Likewise, 
it detected the full- length hGPR37 and mGPR37 in cultured 
cells poorly (see Figure  3A, Figure  S2). These results sug-
gest that GPR37 undergoes proteolytic processing also in 
native brain tissue. The smaller size of receptor species in 
the brain compared to those detected in cultured cells might 
suggest more extensive proteolytic processing of the recep-
tor in the native tissue or otherwise different post- translational 
processing.
Finally, to assess the role of ADAM10 in GPR37 processing 
in the brain, we analyzed samples of various brain regions of 
Adam10cKO mice30 at postnatal day 20. In this mouse model, 
the CamKIIa- Cre promoter was used to obtain deletion of 
ADAM10 after birth, especially in forebrain neurons. The levels 
in the cerebellum, however, remain unaltered. Consistent with 
previous results,28,30 a significant decrease in ADAM10 levels 
was detected in solubilized membrane samples from cortex and 
hippocampus, but not from cerebellum, of the Adam10cKO 
mice compared with the WT littermate controls (Figure 9B,F, 
Figure S6B). The amount of mature ADAM10 was decreased 
to 28 ± 4% and 39 ± 6% in the cortex and hippocampus, re-
spectively and the immature form was practically undetectable 
in the KO mouse samples. This change in the cortex and hip-
pocampus was accompanied by a highly significant increase in 
the 62- kDa mGPR37 detected with the N- terminal antibody 
(2200 ± 420% and 480 ± 445%, respectively) (Figure 9). No 
changes were detected in the cerebellum (Figure S6). Thus, we 
can conclude that ADAM10 is the major protease involved in 
GPR37 processing in the mouse brain.
4 |  DISCUSSION
GPR37 is an orphan GPCR that is abundantly expressed in 
the brain and has been linked to several important physio-
logical functions in health and disease. However, the mech-
anisms of receptor regulation are poorly understood. The 
F I G U R E  7  GPR37 is cleaved at the conserved Arg54↓Asp55 site in the N- terminus by furin. HEK293 (A- E) and LoVo (F) cells were 
transiently transfected with the indicated Myc- hGPR37- FLAG constructs (A- D, F), or alternatively, with the NanoLuc- and HA- tagged 
hGPR37 (E) for 16- 24 hours and treated or not with GI254023X (5 µM), decCMK (20 µM) or marimastat (20 µM) for 20 (A, B, F), 19 (C) or 
12 (D, E) h. Immunoprecipitated receptors from cellular lysates (A, B, F) or aliquots of the concentrated conditioned culture medium without 
immunoprecipitation (D, E) were analyzed by SDS- PAGE and Western blotting. For panel C, cell surface cMyc antibody labeled receptors were 
analyzed by flow cytometry. Triplicate or quadruplicate samples from four independent experiments were analyzed by repeated- measures two- 
way ANOVA and Tukey's multiple comparison test before normalization to the respective controls without the inhibitor- treatment. *P < .05; ns, 
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present study was prompted by our previous finding that the 
receptor undergoes constitutive metalloprotease- mediated 
N- terminal cleavage and is thus present at the cell surface 
mainly in the truncated form.16 Here, we present evidence 
that the processing of GPR37 occurs in two steps involving 
proteases from two enzyme families. The cleavage at the 
previously identified Glu167↓Gln168 site is mediated by the 
well- characterized metalloprotease and sheddase ADAM10. 
Moreover, GPR37 is also cleaved by the PC furin at the con-
served Arg54↓Asp55 site.
Several lines of evidence support the notion that 
ADAM10 is involved in the cleavage and ectodomain 
shedding of human and mouse GPR37. The cleavage was 
inhibited by the ADAM10- selective inhibitor GI254023X 
at low concentrations, and knock- down and knock- out of 
ADAM10 in HEK293 and MEF cells reduced the cleav-
age. In addition, the cleavage could be rescued in the 
HEK293TKO cells by over- expression of WT ADAM10, 
but not by the inactive mutant ADAM10. Furthermore, the 
cleavage was induced in vitro by rADAM10. Finally, the 
conditional KO of Adam10 in mouse neuronal cells was 
found to reduce GPR37 cleavage in the cortex and hippo-
campus in vivo, confirming the physiological relevance 
of ADAM10 as a GPR37 cleaving enzyme. Although sev-
eral membrane- anchored and single- spanning membrane 
proteins have been shown to be processed by ADAM10, 
GPR37, to our knowledge, is the first multispanning mem-
brane protein that has been validated as an ADAM10 
substrate.
While we demonstrate the ADAM10- mediated cleavage 
for both human and mouse GPR37, the results indicate that 
there are some species- specific differences in receptor pro-
cessing. In cultured cells, the human receptor appears to be 
cleaved more efficiently than the mouse receptor at steady 
state conditions and the cleaved C- terminal fragment is 
smaller in size. Moreover, the mouse receptor species are 
smaller in the brain than in cultured cells. These observa-
tions, together with the fact that the N- terminal domain of the 
mouse receptor is shorter in length and sequences around the 
Glu167↓Gln168 cleavage site are not identical (Figure S7), 
indicates a distinct ADAM10 cleavage site for the two recep-
tors and possibly differential regulation. However, we cannot 
exclude the possibility that the primary ADAM10 cleavage 
site of hGPR37 is located upstream of the identified site and 
the receptor is prone to additional processing in a similar 
manner as has been shown for the thyrotropin receptor N- 
terminal domain.43 It can also be suggested that other ADAM 
or MMP family members may compensate ADAM10 func-
tion under certain conditions. For example, they might cleave 
GPR37 under cellular stress conditions, while ADAM10 
cleaves GPR37 in a constitutive manner. In contrast to 
species- specific differences, no clear differences in receptor 
processing were detected in the tested mouse brain regions. 
The specific bands detected with the receptor antibodies were 
heterogenous and wide, but no apparent differences were de-
tected in receptor size or number of species detected.
Although metalloproteases have been shown to cleave 
GPCRs, only a few studies have identified the responsible 
enzymes. The limited proteolysis and shedding of the thy-
rotropin receptor ectodomain have been extensively studied 
and metalloproteases, including ADAMs have been impli-
cated in the process. However, the corresponding enzyme 
has remained under dispute [reviewed44]. The N- terminus 
of the adhesion GPCR B1 (ADGRB1, also known as BAI1) 
is cleaved by MMP14,45 and several MMPs have been sug-
gested to be involved in PAR1 cleavage.46,47 Intriguingly, 
cleavage of PAR1 in a noncanonical site by MMP2 distinct 
from the thrombin cleavage site results in biased signal-
ing,46 suggesting that the metalloprotease- mediated cleav-
age has a role in the functional regulation of the receptor. 
Metalloproteases have also been associated with the proteo-
lytic processing of a few other class A GPCRs but the re-
sponsible enzymes have remained unknown. These receptors 
include the β1- adrenergic receptor,
35,48 V2 vasopressin re-
ceptor,49 C5a receptor,50 sphingosine 1- phosphate receptor,51 
parathyroid hormone 1 receptor52 as well as the endothelin B 
receptor21 and GPR37LI.22 This prevalent role of metallopro-
teases in the cleavage of GPCRs suggests that these enzymes, 
including ADAMs, might be more generally involved in the 
processing and functional regulation of GPCRs.
The mechanisms that determine ADAM10 substrate 
specificity and govern substrate recognition are not fully 
F I G U R E  8  Distinct GPR37 species are detected in the mouse 
brain with antibodies directed against N- and C- terminal domains of 
the receptor. Cellular membranes were isolated from the cerebellum 
(Cb), cortex (Cx), striatum (St), and hippocampus (Hp) of WT and 
GPR37KO mice, and expressed receptors were analyzed by SDS- 
PAGE and Western blotting. The α- actinin was used as a loading 
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understood. Although the protease has been shown to favor 
certain amino acids surrounding the substrate cleavage 
site,53,54 no distinct recognition motif has been identified. 
The distance of the cleavage site from the cell membrane and 
protein conformation appear to be important determinants.33 
Furthermore, the noncatalytic domains of the enzyme play 
a role in defining substrate selectivity. For instance, the 
disintegrin- and cysteine- rich domains of ADAM10 may 
facilitate substrate binding at a distinct site from the metal-
loprotease cleavage site, thus promoting accessibility to the 
cleavage site.55 In line with these notions, we have previously 
reported that mutations at the identified Glu167↓Gln168 
cleavage site are not sufficient to abolish GPR37 cleavage.16 
Surprisingly, the distance between this cleavage site in the 
GPR37 ectodomain and the first transmembrane domain is 
almost 100 amino acids. As ADAM10 typically cleaves its 
substrates close to the plasma membrane, this raises a ques-
tion as to how ADAM10 can access the GPR37 cleavage site. 
One possibility is that the favorable proximity between the 
ADAM10 metalloprotease domain and GPR37 cleavage site 
is attained by conformational rearrangements of the GPR37 
ectodomain. Indeed, it has been shown that the conformation 
of ADAM substrates that enables cleavage is typically tightly 
regulated.56 Additionally, the conformation of ADAM10 
itself can vary depending on its association with different 
members of the TspanC8 subgroup of tetraspanins,57 and this 
could play a role in positioning the metalloprotease domain 
in a favorable orientation to cleave GPR37. It can also be 
speculated that GPR37 and the cleaving enzyme might not 
be in the same cell. Most ADAM10 substrates are cleaved in 
cis within the same cell but the unusual mechanism occurring 
in trans has been demonstrated for ephrin A5.55 In line with 
this, ADAM10 in neurons might cleave the receptor in the 
adjacent glial cells, in which it is abundantly expressed.12,13
In addition to ADAMs, PCs are another family of en-
zymes typically involved in limited proteolysis.24 Like for 
ADAMs, their potential involvement in the processing of 
GPCRs is poorly understood. The PC- mediated cleavage has 
been demonstrated for the adhesion GPCRs G6 (ADGRG6), 
F5 (ADGRF5), and B2 (ADGRB2), also known as GPR126, 
GPR116, and BAI2, respectively.58- 60 In addition, GPR107, 
a proposed GPCR for neuronostatin, is processed by furin.61 
More recently, PCs have been shown to be involved in the 
processing of PAR1 and PAR2.62,63 Thus, PARs provide 
F I G U R E  9  GPR37 is cleaved by 
ADAM10 in the mouse brain. Cellular 
membranes were isolated from the cortex 
(A- C) and hippocampus (D- F) of 20- day- old 
ADAM10cKO mice and the corresponding 
WT littermate controls. The receptor  
(A, D) and ADAM10 (B, E) were analyzed 
by SDS- PAGE and Western blotting. The 
α- actinin was used as a loading control. 
The outlined areas in panels B and E are 
shown with enhanced exposure time. In 
panels C and F, the normalized intensity 
values for the full- length receptor and 
mature ADAM10 are shown as means ± SD 
from three WT and four cKO animals. The 
unpaired t- test was used for the statistical 
comparison. ***P < .001; **P < .01; 
*P < .05; ns, nonsignificant. Abbreviations 
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another example of GPCRs in addition to GPR37 that can be 
cleaved by members of both PC and metalloprotease family 
members at distinct sites in their N- termini.
The N- terminal domain of GPR37 contains several po-
tential cleavage sites for PC- mediated processing, but only 
the highly conserved Arg54↓Asp55 site was found to be used. 
This was supported by the finding that deletions spanning 
this site, but not the other putative sites, blocks the cleavage. 
Mutation of Arg54 to alanine was sufficient for this effect. 
The cleavage was inhibited by the membrane- permeable PC 
inhibitor decCMK, but not by the membrane- impermeable 
hexa- D- arginine, and furthermore, it was abolished in furin- 
deficient LoVo cells, indicating that the cleaving enzyme is 
the trans- Golgi network localized furin. In line with this, the 
full- length receptor is found in abundant amounts in the trans- 
Golgi network.16 The high conservation of the GPR37 furin 
cleavage site in mammals suggests that the PC- mediated pro-
cessing of the receptor has functional relevance. The distal N- 
terminus of GPR37 removed by furin may act as a prodomain 
in a similar manner as has been described for several other 
membrane proteins. Such prodomains have been shown, for 
example, to inhibit the functional activity of the protein or to 
promote protein folding in the early secretory pathway.64
As the limited proteolytic processing of the N- terminal 
domain of PARs and adhesion family GPCRs is intimately 
involved in receptor functional activation,19,20 it is tempt-
ing to speculate a similar role for GPR37 ectodomain pro-
cessing. It can be hypothesized that the new N- terminus 
revealed by limited proteolysis might act as a tethered 
peptide agonist that binds and activates the receptor. 
Alternatively, the shed N- terminal fragment(s) may act as 
ligands for the receptor itself or for other proteins/receptors 
in adjacent cells, or even as a scavenger for the natural yet 
unidentified soluble ligand in the extracellular space. It is 
also possible that limited proteolysis merely represents a 
way to inactivate the receptor, in which case only the full- 
length receptor is expected to be functionally active. Future 
research will reveal whether any of these intriguing possi-
bilities turn out to be accurate.
In summary, we provide evidence that ADAM10 cleaves 
GPR37 in various cell lines of diverse tissue origin as well 
as in a more physiological context in the mouse brain. 
Furthermore, GPR37 ectodomain is subject to additional 
processing mediated by furin. These findings together sup-
port the notion that the two enzyme families ADAMs and 
PCs could be more commonly involved in the processing and 
functional regulation of GPCRs.
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